The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.

NCT Number	NCT05159245
Lead Sponsor	Helsinki University Central Hospital
Conditions	Advanced Cancer, Solid Tumor, Haematological Malignancy
Enrollment	250 participants
Start Date	2021-12-10
Primary Completion	2026-11-25 (estimated)
Study Completion	2026-11-25 (estimated)
Updated on ClinicalTrials.gov	2024-07-15